To investigate variation among neonatal intensive care units (NICUs) in prevalence and management of thrombocytopenia in infants <1500 g.
INTRODUCTION
Neonatal thrombocytopenia remains the most common hemostatic abnormality among very low birth-weight (VLBW) infants in the neonatal intensive care unit (NICU). 1 While certain platelet values separate nonthrombocytopenic from thrombocytopenic and severely thrombocytopenic infants, there are no accepted criteria dictating when to transfuse these infants with platelets. In the absence of accepted guidelines, it is reasonable to expect some practice variability. There are obvious dangers inherent in not transfusing platelets when medically necessary, but also a need to limit the number of unnecessary interventions, especially the administration of unnecessary blood products. It is unclear, however, what risks the presence of moderate thrombocytopenia poses, and what interventions, if any, should be administered. 2 Despite the frequency with which thrombocytopenia is encountered in the NICU, few studies have assessed the efficacy of platelet transfusions for thrombocytopenic infants. One randomized, controlled trial of platelet transfusions found that platelet administration increased platelet counts and shortened bleeding times, but did not reduce the incidence or extent of intracranial hemorrhage in premature infants. 3 Another retrospective study found no hemostatic benefit to transfusing even their most thrombocytopenic neonates. 4 We and others have linked moderate thrombocytopenia to increased clinical bleeding and intraventricular hemorrhage (IVH), 5, 6 but others have found no relation. 2 No inter-NICU studies to date have compared management of birth weight (BW) F and illness severity F matched thrombocytopenic infants. One study reported on practice variation among clinicians at 452 institutions, but listed only the variability in number of transfusions without controlling for degree of thrombocytopenia, illness severity or other risk factors. 7 Their comments on inter-NICU variability in transfusion practice were based on survey questions using theoretical clinical scenarios.
We have addressed the issue of inter-NICU variability in disease prevalence and management in previous studies among a multicenter cohort of VLBW infants in the NICU [8] [9] [10] [11] and have reported on the overall prevalence of thrombocytopenia. 6 In this current study, we made use of the existing multicenter study of this same cohort of infants to investigate the variation in rates and management of thrombocytopenia among NICUs and whether platelet administration had any effect on the incidence of IVH.
MATERIALS AND METHODS Study design
We performed a secondary analysis of data collected as part of a study of NICU outcomes. We prospectively abstracted medical charts of all VLBW infants (BW less than 1500 g) who were admitted to six major regional NICUs during the 21 months from October 1, 1994 to June 30, 1996. Infants who were readmitted, stayed in the NICU less than 24 hours, or were born outside the study sites and were admitted after 24 hours of life were excluded from the study. Upon admission to the NICU, both maternal data (mode of delivery, maternal hypertension, antenatal steroid use and multiple gestation) and neonatal data (presentation, gestational age (GA), BW, Apgar scores and head circumference) were gathered. Small for gestational age (SGA) was determined from BW and GA; infants who were less than the 5th percentile in BW for age were considered SGA.
The Score for Neonatal Acute Physiology (SNAP), a neonatal illness severity index, was computed on study days 1, 3 and 14.
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The SNAP assesses the worst status of an infant during a baseline period of 12 hours for day 1 (24 hours for days 3 and 14) for a variety of physiologic measures (i.e., vital signs, laboratory values and the occurrence of symptoms such as seizures and apnea). The SNAP is the sum of points given for physiologic derangements of each organ system: a higher SNAP indicates a sicker infant. Since platelet count was used to calculate the original SNAP score, a recalculated SNAP score was introduced which excluded this value.
The lowest platelet value obtained on each SNAP scoring day was used as an indication of either no thrombocytopenia (platelet count Z100 Â 10 9 /l), moderate thrombocytopenia (platelet count <100 Â 10 9 /l) or severe thrombocytopenia (platelet count <50 Â 10 9 /l). ''Any thrombocytopenia'' was defined as moderate or severe thrombocytopenia on days 1 and/or 3 of life. On SNAP scoring days, data were also gathered on therapeutic interventions including modes of respiratory support, medications, monitoring, operations or procedures, feeding, use of intravascular catheters and administration of platelet and other transfusions. None of the sites had any specific platelet transfusion guidelines in place at the time of this study; however, a platelet count of 50 Â 10 9 /l was the cutoff generally used by the clinicians at each site when considering the initiation of platelet transfusions in this VLBW cohort of infants. Outcome data were also collected including respiratory distress syndrome, patent ductus arteriosus, pneumothorax, sepsis, congenital anomalies, IVH, seizures and mortality data.
Statistical analysis
Data were entered prospectively into a customized data entry program that allowed for immediate error checking and minimized the problem of missing data. Extensive training and supervision ensured uniformity at all sites. All data management was performed using the Statistical Analysis System (Version 6.09, SAS Corporation, Cary, NC). Univariate analyses were performed using t tests and w 2 tests. In our multivariate logistic regression, we entered risk factors in stages: (1) the infant characteristics, (2) the perinatal/obstetric factors, (3) the newborn factors and finally, (4) a dummy variable for site. Results are stated as the mean±SD or as odds ratios (ORs) with 95% confidence intervals (CIs). We performed two sets of regressions models: (1) predicting the presence of any thrombocytopenia, and (2) predicting the likelihood of platelet transfusion, adjusted for platelet level and other clinical factors that may sway the decision to transfuse.
RESULTS

Population
During the study period, 1572 VLBW infants were admitted (initial admission) to one of the six NICUs. We excluded 83 cases (5.3%) from analyses for the following reasons: the infant was not born at one of the study sites and was admitted after 24 hours of life (n ¼ 18, 1.1%); the infant was transferred out of the NICU within 24 hours of admission (n ¼ 18, 1.1%); or the medical chart was incomplete (n ¼ 67, 4.3%). These exclusions resulted in an initial population base of 1489 infants. Of these 1489 infants, 206 infants (13.8%) were excluded from most of the analyses because they had no platelet counts recorded on day 1 or 3 of admission (n ¼ 53, 3.6%), no cranial ultrasounds performed (n ¼ 169, 11.3%), or they died within the first day of life (n ¼ 36, 2.4%). Some infants had more than one reason for exclusion. The remaining 1283 infants were included for most analyses.
Thrombocytopenia
Prevalence of thrombocytopenia and administration of platelets by site are presented in Table 1 . The NICUs are designated A through F and ranked by increasing prevalence of thrombocytopenia. The number of infants at each site (104 to 349) and the proportion of infants born outside each study site (0 to 9.8%) are withheld to preserve the identity of the sites. Differences in patient populations at the six sites are reflected in the varying GA, SNAPs and percentage of patients with low Apgar scores, as reported previously by Richardson et al. 8 Site-specific differences in prevalence of thrombocytopenia were most marked at sites E and F which had the greatest prevalence of thrombocytopenia.
After controlling for risk factors for thrombocytopenia (e.g., SNAP, SGA and maternal hypertension), including a dummy variable for site, sites A, D, E and F all had significantly greater prevalence rates of thrombocytopenia than would be expected from their population risk factors (ORs 2.0 to 3.8) relative to site C. These analyses were repeated predicting thrombocytopenia only on the day of admission, and on days 1 and 3 combined (excluding day 14), and gave similar results.
Platelet transfusions
The percentages of infants at each site that received platelets on days 1 and/or 3 were low (2.3 to 9.6%, see Table 1 ). Most sites appeared equally likely to transfuse their thrombocytopenic populations (24.2 to 35.7%) except site E, which had one of the greatest prevalences of thrombocytopenia, but the lowest percentage of infants with thrombocytopenia who received platelets (10.3%). After controlling for SNAP, GA, SGA, Apgar score and incidence of thrombocytopenia, the odds of receiving platelets at site E relative to site F (the site with the highest adjusted transfusion rate) was 0.10 (95% CI 0.02 to 0.43).
When all sites were considered in a logistic model, severe thrombocytopenia (OR 40.0, 95% CI 12.8 to 124.2), moderate thrombocytopenia (OR 17.5, 95% CI 7.9 to 38.5) and a high SNAP score (OR 3.2, 95% CI 1.0 to 10.2) were significantly associated with increased number of platelets transfusions.
Outcomes
The number of infants with severe thrombocytopenia at each site (3 to 5) was too small to draw any statistically significant conclusions with regards to outcome differences between infants with moderate and severe thrombocytopenia. Also, the number of infants with any thrombocytopenia at each site (12 to 31) was too small to allow an assessment of the impact of the different transfusion rates on the measured outcome parameters. The percentages of infants at sites A to F with thrombocytopenia who also had IVH were 58, 29, 44, 59, 18 and 48, respectively. Among thrombocytopenic infants, the site with the lowest rate of platelet transfusions was also the site with the lowest rate of IVH (site E). However, the numbers of infants at each site with both conditions (5 to 16) were too small to reach any statistically significant conclusions regarding these data.
Among the entire cohort, we assessed whether platelet administration was associated with IVH and found that after controlling for other risk factors for IVH (SNAP, Apgar score, GA, SGA, gender, race, maternal hypertension, antenatal steroids, thrombocytopenia and site), those infants with a greater incidence of IVH were more likely to have received platelets on days 1 and/or 3 (OR 3.6, 95% CI 1.5 to 8.3).
COMMENTS
Infants with normal or very low platelet values are usually managed consistently, but it is not clear if platelet transfusions are beneficial for infants with moderate levels of thrombocytopenia. Advocates of withholding platelets until demonstration of very low platelet counts argue that thrombocytopenia in the preterm infant in the first 72 hours of life is common and benign, and recovery is most often spontaneous. [13] [14] [15] Proponents of initiating platelet transfusions at higher platelet counts argue that there is no definitive evidence suggesting that thrombocytopenia in this cohort does not predispose to hematologic sequelae such as IVH. Guidelines for the management of thrombocytopenia suggested by the American Association of Blood Banks recommend transfusions for preterm platelet counts less than 50 Â 10 9 /l if asymptomatic and less than 100 Â 10 9 /l if symptomatic. Calhoun et al. 16 proposed similar guidelines in their ''consistent approach to prophylactic platelet transfusions in the NICU,'' a consensus-of-practice document drafted by a select group of neonatologists. It is unknown, however, how physician practice varies regarding administration of platelets in these situations.
In order to fairly evaluate the different NICUs, it was necessary to control for population differences such as BW and illness severity that might either affect the prevalence of thrombocytopenia, or the threshold to respond with a platelet transfusion. The SNAP score has been shown to be a highly significant predictor of morbidity and mortality risk 17 and enabled us to adjust for illness severity. Other risk factors (e.g., SGA and maternal hypertensive disease) were also adjusted to reconcile risk differences among NICUs.
There were both variations in prevalence of thrombocytopenia and in platelet administration at our study sites. This type of inter-NICU variability in disease prevalence and therapeutic intervention has been seen in our previous studies of perinatal risk and severity of illness, 8 administration of blood transfusions, 9 narcotic administration 10 and vasopressor use. 11 Site-specific differences in thrombocytopenia may be real, reflecting variability in the obstetric population, delivery method, duration of labor, incidence of Alternatively, the inter-NICU differences in thrombocytopenia may be a measurement artifact because of the variability in platelet enumeration (how the blood is drawn, the amount of time from blood drawn to platelet counting or the method of platelet counting). However, this is unlikely to explain the large differences in prevalence of thrombocytopenia that we found between the sites. Five of the six sites had overlapping 95% CI with regard to their likelihood to transfuse their thrombocytopenic infants; one site fell outside of these intervals, the clinical significance of which is uncertain. The small differences noted among these sites probably reflect slightly different ''transfusion trigger'' values at which platelets were administered. At site E, the most likely explanation for the very low incidence of platelet transfusions is a markedly low ''transfusion trigger''.
Murray et al. 4 found that thrombocytopenic neonates (and even severely thrombocytopenic neonates [platelet counts <30 Â 10 9 /l]) who did not receive platelet transfusions were no more likely to develop major hemorrhages than their transfused counterparts. They suggest that current transfusion guidelines are safe rather than clinically indicated. Also, Andrew et al. 3 showed that platelet administration to thrombocytopenic infants did not protect them from developing new IVH or extensions of their old ones. Our data showed similar findings, and in fact, we found that those infants who were transfused with platelets actually had a higher incidence of IVH than their non-treated counterparts. This probably represents bias of indication: clinicians may be identifying and transfusing those infants with IVH at higher platelet counts and may also be more prone to transfuse those infants they suspect to have the highest risk of IVH. In addition, we found that site E, the site with the lowest rate of platelet transfusion was also the site with the lowest rate of IVH among thrombocytopenic infants. No conclusions could be drawn from this data though, as they were not statistically significant. Andrew et al. conclude from their study that because thrombocytopenic infants who were transfused with platelets did not have a lower incidence of IVH, thrombocytopenia does not predispose infants to IVH. Our data neither supports nor refutes their conclusion, however, we propose that postnatal therapy for thrombocytopenia may be too late to protect the infant from a perinatal IVH. This is in keeping with our previous finding associating IVH with thrombocytopenia on day 1 of life (and especially with severe thrombocytopenia on day 1), but not with thrombocytopenia on later days of life, and suggests that delivery and/or birth events may be prime determinants of IVH. 6 It is possible that thrombocytopenia is a marker for an IVH that has already occurred, or a marker for a cytokine cascade that is simultaneously affecting platelet counts and white matter vasculature. Indeed, most authorities agree that the majority of cases of IVH do occur early on the first postnatal day or within the first few days of life. 2, 18 There are limitations to this study. First, it is an observational study making use of predefined variables collected for a previous study on the association of thrombocytopenia and delivery method with IVH. 6 Data were collected prospectively and analyzed within a pre-established framework. 10 Second, disease and management data were only sampled on a select number of hospital days and so it is probable that some thrombocytopenia and platelet transfusion data were missed, and vice versa, that some of the recorded thrombocytopenia was transient. However, this should still not explain the large variability noted between some of the NICUs since the days were consistent (i.e., days 1,3 and 14) for all sites. Also, it is likely that our sampling schedule enabled us to investigate infants who were persistently and/or severely thrombocytopenic in the first few days of life in whom platelet therapy and IVH outcome was most relevant. Third, we do not know the exact timing of the IVH in relation to when the platelets were transfused, or whether any IVH occurred prenatally. Although cranial ultrasound readings were accepted up to 21 days postadmission, most were obtained within the first few days of life when IVH was a prevalent issue and when our transfusion data were gathered. Owing to these limitations, our data preclude analyses of platelet transfusion number with regards to other variables such as post-transfusion platelet count and presence of transfusion reaction or other side effects.
In summary, we found variability in rates of thrombocytopenia among NICUs, even after controlling for some risk factors (e.g., SNAP, SGA and maternal hypertension). This variability probably represents varying maternal population and maternal risk factors that were not assessed in this study. One site had a high percentage of infants with thrombocytopenia, but the lowest percentage of infants with thrombocytopenia who received platelet transfusions. This difference could not be explained by illness severity or presence of thrombocytopenia and is most likely attributable to different ''transfusion trigger'' values.
We have, unfortunately, insufficient outcome data. The numbers of IVHs in infants with thrombocytopenia at the various sites were too few to permit an assessment of different rates of complications in the face of thrombocytopenia and clinician interventions. It would have been very informative to know if the neonatal outcome at site E was different than that of the other sites that transfused at much higher rates. Further investigations into this issue would be valuable.
